BUZZ-Danaher falls after quarterly profit miss

Updates

** Shares of life sciences firm Danaher DHR.N fall 8% to $227.99

** DHR posts lower-than-expected Q4 adj. EPS of $2.14 due to weak demand from biotech and pharmaceutical clients, below analysts' estimates of $2.16, according to data compiled by LSEG

** Company forecasts Q1 2025 adjusted core revenue to "decline low-single digits year-over-year"

** Also forecasts FY25 adjusted core rev. to increase about 3% year-over-year

** Brokerage Leerink Partners says FY25 revenue forecast "well below the Street at ~3% org vs ~5% org" but adds it continues to see DHR as "a sector leader and an M&A compounder" with a market-leading franchise in bioprocessing despite near-term challenges

** Brokerage adds that the company's 2025 and Q1 2025 forecasts are well below consensus, driven mostly by diagnostics and life sciences segments

** DHR was up 7.5% in the past 12 months